Holen Sie sich die Stockscreener-App
18.23
0.66%
0.12
Handel nachbörslich:
18.23
Schlusskurs vom Vortag:
$18.11
Offen:
$18.96
24-Stunden-Volumen:
933.26K
Relative Volume:
1.82
Marktkapitalisierung:
$1.37B
Einnahmen:
$62.71M
Nettoeinkommen (Verlust:
$-112.51M
KGV:
-12.07
EPS:
-1.51
Netto-Cashflow:
$-96.01M
1W Leistung:
+10.48%
1M Leistung:
+15.82%
6M Leistung:
+65.73%
1J Leistung:
+37.07%
1-Tages-Spanne:
$17.94
$19.50
1-Wochen-Bereich:
$16.42
$19.50
52-Wochen-Spanne:
$9.03
$19.50
Zymeworks Inc. Stock (ZYME) Company Profile
Firmenname
Zymeworks Inc.
Sektor
Branche
Telefon
604-678-1388
Adresse
1385 West 8th Avenue, Suite 540, Vancouver, BC
Vergleichen Sie ZYME mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
18.23 | 1.37B | 62.71M | -112.51M | -96.01M | -1.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Eingeleitet | B. Riley Securities | Buy |
| 2025-05-20 | Eingeleitet | TD Cowen | Buy |
| 2024-12-16 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-11-07 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | Fortgesetzt | Wells Fargo | Overweight |
| 2023-01-04 | Bestätigt | H.C. Wainwright | Neutral |
| 2022-12-20 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-05-05 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-03-15 | Eingeleitet | Evercore ISI | Outperform |
| 2021-12-10 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | Fortgesetzt | Guggenheim | Neutral |
| 2021-10-07 | Eingeleitet | Jefferies | Hold |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2021-02-25 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-08-06 | Eingeleitet | SVB Leerink | Outperform |
| 2020-01-10 | Eingeleitet | Wolfe Research | Outperform |
| 2019-12-09 | Eingeleitet | JP Morgan | Neutral |
| 2019-11-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-20 | Eingeleitet | Guggenheim | Buy |
| 2019-09-30 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | Eingeleitet | Stifel | Buy |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2018-05-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-03-19 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Zymeworks Inc. Aktie (ZYME) Neueste Nachrichten
Zymeworks (NASDAQ:ZYME) Shares Gap UpHere's Why - MarketBeat
This RPM International Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Benzinga
Will Zymeworks Inc. stock attract ESG investorsPortfolio Performance Report & Pattern Based Trade Signal System - newser.com
Will Zymeworks Inc. stock sustain high P E ratios2025 Market Outlook & AI Driven Stock Movement Reports - newser.com
What the charts say about Zymeworks Inc. today2025 Technical Patterns & Free Expert Approved Momentum Trade Ideas - newser.com
How Zymeworks Inc. stock compares to market leadersJuly 2025 Gainers & Expert Approved Momentum Trade Ideas - newser.com
Will Zymeworks Inc. stock outperform growth indexesQuarterly Performance Summary & Scalable Portfolio Growth Ideas - newser.com
Zymeworks to present early data on ZW191 cancer drug at conference - Investing.com Nigeria
Zymeworks to present early data on ZW191 cancer drug at conference By Investing.com - Investing.com South Africa
Zymeworks Presents Preliminary Phase 1 Results for ZW191 Targeting Advanced Solid Tumors at AACR-NCI-EORTC Conference - Quiver Quantitative
Zymeworks to Present Clinical Data from the Phase 1 trial - GlobeNewswire
Phase 1 preliminary data: ZW191 (FRα-targeting ADC) — Zymeworks to present at AACR Oct 23 - Stock Titan
Applying Elliott Wave Theory to Zymeworks Inc.Breakout Watch & Comprehensive Market Scan Reports - newser.com
Using economic indicators to assess Zymeworks Inc. potentialOptions Play & Community Consensus Picks - newser.com
What technical models suggest about Zymeworks Inc.’s comebackQuarterly Performance Summary & Precise Swing Trade Alerts - newser.com
Zymeworks (ZYME): Evaluating Valuation Following New Leadership and Key Regulatory Wins - Sahm
Is Zymeworks Inc. showing signs of accumulationForecast Cut & Short-Term Trading Alerts - newser.com
Will Zymeworks’ (ZYME) New R&D Leadership Mark a Turning Point in Its Oncology Strategy? - Yahoo
Zymeworks (NYSE:ZYME) Stock Price Up 7.2%Here's What Happened - MarketBeat
Zymeworks (NASDAQ:ZYME) Reaches New 52-Week HighHere's Why - MarketBeat
Zymeworks stock hits 52-week high at 17.71 USD By Investing.com - Investing.com Canada
How Might ZYME’s Shifting Leadership Shape Its Late-Stage Oncology Ambitions? - simplywall.st
B. Riley Securities Initiates Coverage of Zymeworks (ZYME) with Buy Recommendation - Nasdaq
Zymeworks stock hits 52-week high at 17.71 USD - Investing.com
Zymeworks (ZYME) Coverage Initiated by B. Riley Securities with 'Buy' Rating | ZYME Stock News - GuruFocus
Lifesci Capital Forecasts Zymeworks' Q3 Earnings (NYSE:ZYME) - MarketBeat
Zymeworks appoints Adam Schayowitz as acting chief development officer By Investing.com - Investing.com Nigeria
Zymeworks Appoints New Acting Chief Development Officer to Boost Therapeutic Advancements - TipRanks
Zymeworks appoints Adam Schayowitz as acting chief development officer - Investing.com India
Zymeworks Inc. Appoints Adam Schayowitz, Ph.D., MBA as Acting Chief Development Officer - Quiver Quantitative
Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer - The Spec
Q1 Earnings Forecast for Zymeworks Issued By Lifesci Capital - MarketBeat
How to forecast Zymeworks Inc. trends using time series2025 Dividend Review & Community Consensus Trade Alerts - newser.com
Is Zymeworks Inc a good long term investmentShort-Term Trading Alerts & Small Capital Trading Plans - earlytimes.in
Is Zymeworks Inc. stock entering bullish territoryPortfolio Risk Report & Free Fast Gain Swing Trade Alerts - newser.com
Why analysts maintain buy rating on Zymeworks Inc. (ZA8) stockJuly 2025 Patterns & Precise Swing Trade Entry Alerts - newser.com
Market reaction to Zymeworks Inc.’s recent news2025 Dividend Review & Technical Buy Zone Confirmation - newser.com
Key resistance and support levels for Zymeworks Inc.Quarterly Portfolio Review & Reliable Entry Point Alerts - newser.com
Zymeworks (ZYME): Assessing Valuation Following Recent Momentum in Biopharma - Sahm
Will Zymeworks Inc. stock outperform tech sector in 2025July 2025 Analyst Calls & Scalable Portfolio Growth Ideas - newser.com
Will Zymeworks Inc. stock recover faster than peersQuarterly Profit Summary & Daily Volume Surge Signals - newser.com
How Zymeworks Inc. (ZA8) stock stacks up against competitorsJuly 2025 Fed Impact & Fast Gain Swing Trade Alerts - newser.com
Finanzdaten der Zymeworks Inc.-Aktie (ZYME)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):